Echo Therapeutics (NASDAQ:ECTE) reported Q1 EPS of ($0.23), $0.08 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $19.11 thousand versus the consensus estimate of $20 thousand. Echo Therapeutics Inc. (NASDAQ:ECTE) weekly performance is -32.08%. On last trading day company shares ended up $2.16. Analysts mean target price for the company is $6.50. Echo Therapeutics Inc. (NASDAQ:ECTE) distance from 50-day simple moving average (SMA50) is -31.82%.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) announced that the company’s board of directors has elected Ted W. Love, M.D. as the Chairman, effective May 1, 2014. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) shares fell -10.00% in last trading session and ended the day on $1.89. KBIO return on assets is -71.60%.KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) quarterly performance is -33.22%.
On April 4, 2014, Ventrus Biosciences, Inc. (NASDAQ:VTUS) issued a press release announcing that the U.S. Food and Drug Administration has scheduled a Type B pre-NDA meeting on June 19, 2014 at which the company will seek guidance on its planned new drug application for DOLIZEM (diltiazem hydrochloride cream) in anal fissures. Ventrus Biosciences Inc. (NASDAQ:VTUS) shares moved down -5.88% in last trading session and was closed at $0.960, while trading in range of $0.91 – $1.05. Ventrus Biosciences Inc. (NASDAQ:VTUS) year to date (YTD) performance is -74.87%.
As of March 31, 2014, Heron Therapeutics Inc. (NASDAQ:HRTX) had approximately $57.5 million in cash, compared to $72.3 million as of December 31, 2013. Net cash used in operating activities was $15.7 million for the quarter ended March 31, 2014. Heron Therapeutics’ net loss for the first quarter of 2014 was $17.5 million, or $0.74 per share, compared to a net loss of $13.0 million, or $0.85 per share, for the first quarter of 2013. Heron Therapeutics Inc. (NASDAQ:HRTX) ended the last trading day at $11.31. Company weekly volatility is calculated as 7.69% and price to cash ratio as 3.74.Heron Therapeutics Inc. (NASDAQ:HRTX) showed a negative weekly performance of -11.29%.
Alimera Sciences Inc. (NASDAQ:ALIM) Revenue for the first quarter of 2014 was $2.1 million compared to total revenue of $935,000 in the fourth quarter of 2013. GAAP cost of goods sold were $564,000 for the first quarter of 2014 and GAAP gross profit was $1.5 million. Alimera Sciences Inc. (NASDAQ:ALIM) weekly performance is -12.07%. On last trading day company shares ended up $5.17. Analysts mean target price for the company is $7.00. Alimera Sciences Inc. (NASDAQ:ALIM) distance from 50-day simple moving average (SMA50) is -21.50%.